{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:43:26Z","timestamp":1792413806206,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The supplementary budget of the National Institutes of Biomedical Innovation, Health and Nutrition"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K15173"],"award-info":[{"award-number":["24K15173"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The molecular mechanisms underlying many drug-induced diseases, namely, the adverse effects caused by medications, remain poorly understood. As we consider that adverse effects result from the unintended targets of a drug, we aimed to clarify the molecular mechanisms of drug-induced diseases based on information regarding off-target interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>First, off-targets were searched in public databases, and four proteins were selected. Subsequently, rare and intractable diseases caused by drugs targeting the proteins were identified through side-effect information. Further, the pharmacological actions of the drugs on the targets and related substructures were investigated using statistical analysis and substructure search.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the four proteins, one of the ATP-binding cassette (ABC) transporters, ABCG2, was related to a severe disease, interstitial lung disease (ILD): drugs inducing ILD showed a strong tendency to bind and inhibit ABCG2 and kinases. Moreover, these drugs tended to contain pyrimidine and methoxyethane, both of which are effective at inhibiting ABCG2 and kinases, as substructures. Drugs satisfying both conditions of \u201cbinding to ABCG2\/kinase\u201d and \u201chaving substructure pyrimidine\/methoxyethane\u201d were more associated with ILD compared with drugs satisfying only one condition. Among the drugs reported to be associated with a high incidence of ILD, many were strong inhibitors of ABCG2 with or without kinase inhibitory activity; however, some drugs showed little evidence of binding to ABCG2 or kinases. Examples of the latter included folic acid (FA) antagonists, which are known to induce pulmonary fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that for kinase inhibitors known to induce ILD, inhibition of off-target ABCG2 as well as kinases is likely to be associated with the disease and that many drugs inducing ILD other than known kinase inhibitors also inhibit ABCG2. Some drugs with little evidence of binding to ABCG2 include antifolates, raising the possibility that abnormal FA metabolism is one of the common phenomena of drug-induced ILD, particularly as ABCG2 is a folate efflux transporter related to tissue folate absorption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01559-5","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:55:26Z","timestamp":1784634926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drugs inducing interstitial lung disease: in silico analysis of their structures and targets"],"prefix":"10.1186","volume":"32","author":[{"given":"Mao","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokichi","family":"Takahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Sakate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"1559_CR1","doi-asserted-by":"publisher","first-page":"4276s","DOI":"10.1158\/1078-0432.CCR-040010","volume":"10","author":"AA Adjei","year":"2004","unstructured":"Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004;10:4276s\u201380s.","journal-title":"Clin Cancer Res"},{"key":"1559_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","volume":"9","author":"YG Assaraf","year":"2006","unstructured":"Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat. 2006;9:227\u201346.","journal-title":"Drug Resist Updat"},{"key":"1559_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1039\/D0MD00227E","volume":"11","author":"DJ Baillache","year":"2020","unstructured":"Baillache DJ, Unciti-Broceta A. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4- d]pyrimidine scaffold. RSC Med Chem. 2020;11:1112\u201335.","journal-title":"RSC Med Chem"},{"key":"1559_CR4","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1124\/dmd.113.053140","volume":"41","author":"J Bakhsheshian","year":"2013","unstructured":"Bakhsheshian J, Hall MD, Robey RW, et al. Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos. 2013;41:1805\u201312.","journal-title":"Drug Metab Dispos"},{"key":"1559_CR5","first-page":"e20240110","volume":"50","author":"GDP Bridi","year":"2024","unstructured":"Bridi GDP, Fonseca EKUN, Kairalla RA, et al. Drug-induced lung disease: a narrative review. J Bras Pneumol. 2024;50:e20240110.","journal-title":"J Bras Pneumol"},{"key":"1559_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1517\/17425255.2011.562892","volume":"7","author":"A Br\u00f3zik","year":"2011","unstructured":"Br\u00f3zik A, Heged\u00fcs C, Erdei Z, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 2011;7:623\u201342.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1559_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0049-0172(87)90021-7","volume":"16","author":"CW Carson","year":"1987","unstructured":"Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987;16:186\u201395.","journal-title":"Semin Arthritis Rheum"},{"key":"1559_CR8","unstructured":"ChEMBL\u00a0https:\/\/www.ebi.ac.uk\/chembl\/."},{"key":"1559_CR9","doi-asserted-by":"publisher","first-page":"baw009","DOI":"10.1093\/database\/baw009","volume":"2016","author":"Y-A Chen","year":"2016","unstructured":"Chen Y-A, Tripathi LP, Mizuguchi K. An integrative data analysis platform for gene set analysis and knowledge discovery in a data warehouse framework. Database (Oxford). 2016;2016:baw009.","journal-title":"Database (Oxford)"},{"key":"1559_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1124\/dmd.118.080663","volume":"46","author":"RR Crawford","year":"2018","unstructured":"Crawford RR, Potukuchi PK, Schuetz EG, et al. Beyond competitive inhibition: regulation of ABC transporters by kinases and protein-protein interactions as potential mechanisms of drug-drug interactions. Drug Metab Dispos. 2018;46:567\u201380.","journal-title":"Drug Metab Dispos"},{"key":"1559_CR11","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s11095-014-1389-0","volume":"31","author":"J Deng","year":"2014","unstructured":"Deng J, Shao J, Markowitz JS, An G. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm Res. 2014;31:2237\u201355.","journal-title":"Pharm Res"},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"106362","DOI":"10.1016\/j.ejps.2022.106362","volume":"181","author":"F Deng","year":"2023","unstructured":"Deng F, Sj\u00f6stedt N, Santo M, et al. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs. Eur J Pharm Sci. 2023;181:106362.","journal-title":"Eur J Pharm Sci"},{"key":"1559_CR13","unstructured":"DrugBank. https:\/\/go.drugbank.com\/. Accessed Jan 2025."},{"key":"1559_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","volume":"95","author":"LN Eadie","year":"2014","unstructured":"Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014;95:294\u2013306.","journal-title":"Clin Pharmacol Ther"},{"key":"1559_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"WE Evans","year":"2003","unstructured":"Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538\u201349.","journal-title":"N Engl J Med"},{"key":"1559_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86:301\u20137.","journal-title":"Joint Bone Spine"},{"key":"1559_CR17","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","volume":"45","author":"A Gaulton","year":"2017","unstructured":"Gaulton A, Hersey A, Nowotka M, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45:D945\u201354.","journal-title":"Nucleic Acids Res"},{"key":"1559_CR18","doi-asserted-by":"publisher","first-page":"107468","DOI":"10.1016\/j.vascn.2023.107468","volume":"123","author":"JR Green","year":"2023","unstructured":"Green JR, Mahalingaiah PKS, Gopalakrishnan SM, et al. Off-target pharmacological activity at various kinases: potential functional and pathological side effects. J Pharmacol Toxicol Methods. 2023;123:107468.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1559_CR19","doi-asserted-by":"publisher","first-page":"25527","DOI":"10.1074\/jbc.M401725200","volume":"279","author":"I Ifergan","year":"2004","unstructured":"Ifergan I, Shafran A, Jansen G, et al. Folate deprivation results in the loss of breast cancer resistance protein (BCRP\/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem. 2004;279:25527\u201334.","journal-title":"J Biol Chem."},{"key":"1559_CR20","doi-asserted-by":"publisher","first-page":"204209862312242","DOI":"10.1177\/20420986231224227","volume":"15","author":"T Jiang","year":"2004","unstructured":"Jiang T, Su H, Xu J, et al. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2021. Ther Adv Drug Saf. 2004;15:20420986231224228.","journal-title":"Ther Adv Drug Saf"},{"key":"1559_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/thoraxjnl-2020-215824","volume":"76","author":"T Jo","year":"2021","unstructured":"Jo T, Michihata N, Yamana H, et al. Risk of drug-induced interstitial lung disease in hospitalised patients: a nested case-control study. Thorax. 2021;76:1193\u20139.","journal-title":"Thorax"},{"key":"1559_CR22","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1039\/D5MD00235D","volume":"16","author":"A Jug","year":"2025","unstructured":"Jug A, Ilas J. ATP-competitive inhibitors for cancer treatment \u2013kinases and the world beyond. RSC Med Chem. 2025;16:4044\u201367.","journal-title":"RSC Med Chem"},{"key":"1559_CR23","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa M, Furumichi M, Sato Y, et al. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 2025;53:D672\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1559_CR24","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1001\/archderm.1978.01640240042014","volume":"114","author":"RL Kaplan","year":"1978","unstructured":"Kaplan RL, Waite DH. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol. 1978Dec;114:1800\u20132.","journal-title":"Arch Dermatol"},{"key":"1559_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1\u201317.","journal-title":"Drug Resist Updat"},{"key":"1559_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bbrc.2018.02.111","volume":"497","author":"M Kawami","year":"2018","unstructured":"Kawami M, Harabayashi R, Harada R, et al. Folic acid prevents methotrexate-induced epithelial-mesenchymal transition via suppression of secreted factors from the human alveolar epithelial cell line A549. Biochem Biophys Res Commun. 2018;497:457\u201363.","journal-title":"Biochem Biophys Res Commun"},{"key":"1559_CR27","unstructured":"KEGG. https:\/\/www.kegg.jp\/kegg\/. Accessed Sep 2024 and July 2025."},{"key":"1559_CR28","doi-asserted-by":"publisher","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","volume":"39","author":"C Knox","year":"2011","unstructured":"Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for \u201comics\u201d research on drugs. Nucleic Acids Res. 2011;39:D1035\u201341.","journal-title":"Nucleic Acids Res"},{"key":"1559_CR29","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 2024;52:D1265\u201375.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"1559_CR30","doi-asserted-by":"publisher","first-page":"D401","DOI":"10.1093\/nar\/gkt1207","volume":"42","author":"M Kuhn","year":"2014","unstructured":"Kuhn M, Szklarczyk D, Pletscher-Frankild S, et al. STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res. 2014;42(Database issue):D401\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1559_CR31","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn M, Letunic I, Jensen LJ, et al. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44:D1075\u20139.","journal-title":"Nucleic Acids Res"},{"key":"1559_CR32","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.23677","volume":"123","author":"C Lemos","year":"2008","unstructured":"Lemos C, Kathmann I, Giovannetti E, et al. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer. 2008;123:1712\u201320.","journal-title":"Int J Cancer"},{"key":"1559_CR33","doi-asserted-by":"publisher","first-page":"1658001","DOI":"10.3389\/fmed.2025.1658001","volume":"12","author":"W Li","year":"2025","unstructured":"Li W, Xie Y, Chen Z, et al. Epithelial-mesenchymal transition in pulmonary fibrosis: molecular mechanisms and emerging therapeutic strategies. Front Med (Lausanne). 2025;12:1658001.","journal-title":"Front Med (Lausanne)"},{"key":"1559_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-981-13-7647-4_2","volume":"1141","author":"X Liu","year":"2019","unstructured":"Liu X. ABC family transporters. Adv Exp Med Biol. 2019;1141:13\u2013100.","journal-title":"Adv Exp Med Biol"},{"key":"1559_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1039\/D3SC04690G","volume":"15","author":"YL Liu","year":"2023","unstructured":"Liu YL, Zhang M, Jang H, et al. The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization. Chem Sci. 2023;15:1003\u201317.","journal-title":"Chem Sci"},{"key":"1559_CR36","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1590\/S0021-75572007000700007","volume":"83","author":"CA Longui","year":"2007","unstructured":"Longui CA. Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio j). 2007;83:S163\u201377.","journal-title":"J Pediatr (Rio j)"},{"key":"1559_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","volume":"13","author":"O Matsuno","year":"2012","unstructured":"Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39.","journal-title":"Respir Res"},{"key":"1559_CR38","unstructured":"Ministry of Health, Labour and Welfare: Designated Intractable Diseases. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000084783.html."},{"key":"1559_CR39","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1021\/acs.jmedchem.0c02199","volume":"64","author":"V Namasivayam","year":"2021","unstructured":"Namasivayam V, Silbermann K, Wiese M, et al. C@PA: computer-aided pattern analysis to predict multitarget ABC transporter inhibitors. J Med Chem. 2021;64:3350\u201366.","journal-title":"J Med Chem"},{"key":"1559_CR40","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/bioinformatics\/btab832","volume":"38","author":"V Namasivayam","year":"2022","unstructured":"Namasivayam V, Stefan K, Silbermann K, et al. Structural feature-driven pattern analysis for multitarget modulator landscapes. Bioinformatics. 2022;38:1385\u201392.","journal-title":"Bioinformatics"},{"key":"1559_CR41","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1349-7006.2009.01213.x","volume":"100","author":"K Noguchi","year":"2009","unstructured":"Noguchi K, Kawahara H, Kaji A, et al. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009;100:1701\u20137.","journal-title":"Cancer Sci"},{"key":"1559_CR42","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.2169\/internalmedicine.2548-18","volume":"58","author":"R Otoshi","year":"2019","unstructured":"Otoshi R, Sekine A, Hagiwara E, et al. Pemetrexed-induced interstitial lung disease mimicking hypersensitivity pneumonia: a pathologically proven case. Intern Med. 2019;58:2679\u201382.","journal-title":"Intern Med"},{"key":"1559_CR43","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, V\u00e1rady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004;65:1485\u201395.","journal-title":"Mol Pharmacol"},{"key":"1559_CR44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nbt1228","volume":"24","author":"GV Paolini","year":"2006","unstructured":"Paolini GV, Shapland RHB, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol. 2006;24:805\u201315.","journal-title":"Nat Biotechnol"},{"key":"1559_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0190-9622(87)70052-8","volume":"16","author":"TJ Phillips","year":"1987","unstructured":"Phillips TJ, Jones DH, Baker H. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol. 1987;16:373\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"1559_CR46","doi-asserted-by":"publisher","first-page":"110711","DOI":"10.1016\/j.biopha.2020.110711","volume":"131","author":"Y Qu","year":"2020","unstructured":"Qu Y, Hao C, Zhai R, et al. Folate and macrophage folate receptor-\u03b2 in idiopathic pulmonary fibrosis disease: the potential therapeutic target? Biomed Pharmacother. 2020;131:110711.","journal-title":"Biomed Pharmacother"},{"key":"1559_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fdata.2019.00025","volume":"2","author":"MS Rao","year":"2019","unstructured":"Rao MS, Gupta R, Liguori MJ, et al. Novel computational approach to predict off-target interactions for small molecules. Front Big Data. 2019;2:25.","journal-title":"Front Big Data"},{"key":"1559_CR48","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3390\/nu13114036","volume":"13","author":"AE Ratajczak","year":"2021","unstructured":"Ratajczak AE, Szymczak-Tomczak A, Rychter AM, et al. Does folic acid protect patients with inflammatory bowel disease from complications? Nutrients. 2021;13:4036.","journal-title":"Nutrients"},{"key":"1559_CR49","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res. 2020;152:104609.","journal-title":"Pharmacol Res"},{"key":"1559_CR50","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","volume":"23","author":"A Sajid","year":"2023","unstructured":"Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer. 2023;23:762\u201379.","journal-title":"Nat Rev Cancer"},{"key":"1559_CR51","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/ph16040534","volume":"16","author":"A \u0218andor","year":"2023","unstructured":"\u0218andor A, Ionu\u021b I, Marc G, et al. Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). Pharmaceuticals (Basel). 2023;16:534.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1559_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T, et al. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63\u201374.","journal-title":"Open Respir Med J"},{"key":"1559_CR53","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.crchbi.2022.100040","volume":"3","author":"RAM Serafim","year":"2023","unstructured":"Serafim RAM, Haarer L, Pedreira JGB, et al. Covalent chemical probes for protein kinases. Curr Res Chem Biol. 2023;3:100040.","journal-title":"Curr Res Chem Biol"},{"key":"1559_CR54","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.3390\/ijms22168838","volume":"22","author":"PW Shen","year":"2021","unstructured":"Shen PW, Ho CT, Hsiao SH, Chou YT, et al. Disruption of cytosolic folate integrity aggravates resistance to epidermal growth factor receptor tyrosine kinase inhibitors and modulates metastatic properties in non-small-cell lung cancer cells. Int J Mol Sci. 2021;22:8838.","journal-title":"Int J Mol Sci"},{"key":"1559_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/dmd.108.024612","volume":"37","author":"S Shukla","year":"2009","unstructured":"Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37:359\u201365.","journal-title":"Drug Metab Dispos"},{"key":"1559_CR56","unstructured":"SIDER 4.1: Side Effect Resource. http:\/\/sideeffects.embl.de\/. Accessed Sep 2025."},{"key":"1559_CR57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7:356.","journal-title":"J Clin Med"},{"key":"1559_CR58","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","volume":"60","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. Eur Respir J. 2022;60:2102776.","journal-title":"Eur Respir J"},{"key":"1559_CR59","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.4155\/fmc-2019-0185","volume":"11","author":"SM Stefan","year":"2019","unstructured":"Stefan SM. Multi-target ABC transporter modulators: what next and where to go? Future Med Chem. 2019;11:2353\u20138.","journal-title":"Future Med Chem"},{"key":"1559_CR60","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41597-022-01506-z","volume":"9","author":"SM Stefan","year":"2022","unstructured":"Stefan SM, Jansson PJ, Pahnke J, et al. A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors. Sci Data. 2022;9:446.","journal-title":"Sci Data."},{"key":"1559_CR61","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"SS Sunder","year":"2023","unstructured":"Sunder SS, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8:262.","journal-title":"Signal Transduct Target Ther"},{"key":"1559_CR62","doi-asserted-by":"publisher","first-page":"19358","DOI":"10.1038\/s41598-023-46648-1","volume":"13","author":"M Tanabe","year":"2023","unstructured":"Tanabe M, Sakate R, Nakabayashi J, et al. A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases. Sci Rep. 2023;13:19358.","journal-title":"Sci Rep"},{"key":"1559_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","volume":"152","author":"T Terada","year":"2015","unstructured":"Terada T, Noda S, Inui KI. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125\u201334.","journal-title":"Pharmacol Ther"},{"key":"1559_CR64","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jjco\/hyx010","volume":"47","author":"K Tomii","year":"2017","unstructured":"Tomii K, Kato T, Takahashi M, et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer). Jpn J Clin Oncol. 2017;47:350\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"1559_CR65","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1021\/cb200435y","volume":"17","author":"G Valdameri","year":"2012","unstructured":"Valdameri G, Rangel LP, Spatafora C, et al. Methoxy stilbenes as potent, specific, untransported, and\u3000noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem Biol. 2012;17:322\u201330.","journal-title":"ACS Chem Biol"},{"key":"1559_CR66","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1021\/jm2016528","volume":"55","author":"G Valdameri","year":"2012","unstructured":"Valdameri G, Gauthier C, Terreux R, et al. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem. 2012;55:3193\u2013200.","journal-title":"J Med Chem"},{"key":"1559_CR67","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.bcp.2004.11.002","volume":"69","author":"JJ van Zanden","year":"2005","unstructured":"van Zanden JJ, Wortelboer HM, Bijlsma S, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol. 2005;69:699\u2013708.","journal-title":"Biochem Pharmacol"},{"key":"1559_CR68","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-physiol-020911-153251","volume":"76","author":"M Visentin","year":"2014","unstructured":"Visentin M, Diop-Bove N, Zhao R, Goldman ID. The intestinal absorption of folates. Annu Rev Physiol. 2014;76:251\u201374.","journal-title":"Annu Rev Physiol"},{"key":"1559_CR69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4155\/fmc-2020-0236","volume":"13","author":"ED Vita","year":"2021","unstructured":"Vita ED. 10 years into the resurgence of covalent drugs. Future Med Chem. 2021;13:193\u2013210.","journal-title":"Future Med Chem"},{"key":"1559_CR70","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/138920010792927316","volume":"11","author":"XK Wang","year":"2010","unstructured":"Wang XK, Fu LW. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. Curr Drug Metab. 2010;11:618\u201328.","journal-title":"Curr Drug Metab"},{"key":"1559_CR71","doi-asserted-by":"publisher","first-page":"634607","DOI":"10.3389\/fcell.2021.634607","volume":"9","author":"S Wei","year":"2021","unstructured":"Wei S, Ma W, Zhang B, et al. NLRP3 Inflammasome: a promising therapeutic target for drug-induced toxicity. Front Cell Dev Biol. 2021;9:634607.","journal-title":"Front Cell Dev Biol"},{"key":"1559_CR72","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-015-0275-x","volume":"34","author":"D Westover","year":"2015","unstructured":"Westover D, Li F. New trends for overcoming ABCG2\/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:159.","journal-title":"J Exp Clin Cancer Res"},{"key":"1559_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-018-0775-3","volume":"17","author":"S Wu","year":"2018","unstructured":"Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17:25.","journal-title":"Mol Cancer"},{"key":"1559_CR74","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1158\/1535-7163.1119.3.9","volume":"3","author":"K Yanase","year":"2004","unstructured":"Yanase K, Tsukahara S, Asada S, et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther. 2004;3:1119\u201325.","journal-title":"Mol Cancer Ther"},{"key":"1559_CR75","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40780-025-00468-9","volume":"11","author":"J Yayan","year":"2025","unstructured":"Yayan J, Rasche K. Drug-induced interstitial lung disease: a pharmacovigilance study of twelve immunomodulatory and antineoplastic agents. J Pharm Health Care Sci. 2025;11:60.","journal-title":"J Pharm Health Care Sci"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01559-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:02:13Z","timestamp":1792411333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01559-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01559-5","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"190"}}